These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31712951)

  • 1. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Smibert OC; Slavin MA; Teh B; Heriot AG; Penno J; Ismail H; Thursky KA; Worth LJ
    Support Care Cancer; 2020 Jun; 28(6):2745-2752. PubMed ID: 31712951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious Complications after Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy.
    Arslan NC; Sokmen S; Avkan-Oguz V; Obuz F; Canda AE; Terzi C; Fuzun M
    Surg Infect (Larchmt); 2017; 18(2):157-163. PubMed ID: 27906610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
    Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes.
    Robella M; Vaira M; Cinquegrana A; De Simone M
    Minerva Chir; 2019 Jun; 74(3):195-202. PubMed ID: 29589675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Iavazzo C; Spiliotis J
    Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy.
    Eng OS; Raoof M; O'Leary MP; Lew MW; Wakabayashi MT; Paz IB; Melstrom LG; Lee B
    Surg Infect (Larchmt); 2018; 19(6):618-621. PubMed ID: 30044187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
    Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 16. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.
    Foster JM; Sleightholm R; Patel A; Shostrom V; Hall B; Neilsen B; Bartlett D; Smith L
    JAMA Netw Open; 2019 Jan; 2(1):e186847. PubMed ID: 30646202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
    Saxena A; Valle SJ; Liauw W; Morris DL
    Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the measurement of sarcopenia associated with oncological disease in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
    Siu AHY; Holyland M; Carey S; Steffens D; Ansari N; Koh CE
    ANZ J Surg; 2023 Sep; 93(9):2186-2191. PubMed ID: 37525364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.
    Riss S; Chandrakumaran K; Dayal S; Cecil TD; Mohamed F; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):392-5. PubMed ID: 25238953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.